Corcept Therapeutics Q2 2025 Earnings Report

Corcept Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.23
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Corcept Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Corcept Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: Monday, July 28, 2025
• Conference Call Time: 5:00PM ET

Corcept Therapeutics (NASDAQ:CORT) is a biopharmaceutical company focused on the development and commercialization of therapies that modulate the effects of cortisol, a hormone implicated in a range of serious medical conditions. Founded in 1998 and headquartered in Menlo Park, California, the company emerged from research into cortisol receptor antagonists. Corcept’s strategy centers on advancing novel small-molecule drugs that address disorders driven by excessive cortisol activity, with a strong emphasis on regulatory approval and patient access.

The company’s lead product, Korlym (mifepristone), is approved for the treatment of hyperglycemia secondary to Cushing’s syndrome in adults who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Korlym represents the first and only cortisol receptor antagonist indicated for this rare endocrine disorder. Corcept has built a dedicated commercial infrastructure in the United States and has expanded access programs to support patients and physicians in managing the complexities of Cushing’s syndrome.

Beyond Korlym, Corcept maintains an active pipeline of next-generation compounds designed to target a variety of cortisol-related and other serious diseases. These programs include selective glucocorticoid receptor antagonists under clinical investigation for applications in oncology, metabolic disorders and psychiatric conditions. The company collaborates with academic institutions and research organizations to advance translational studies and optimize dosing strategies for its investigational therapies.

Under the leadership of CEO Kathleen M. Healey and a team of experienced industry professionals, Corcept Therapeutics is committed to improving the lives of patients with life-altering diseases. The company leverages a patient-centric model that integrates regulatory expertise, scientific innovation and robust commercial capabilities. Corcept serves healthcare providers across North America and Europe, upholding a mission to deliver safe and effective treatments for conditions driven by cortisol dysregulation.